Peter G. Falkai
Elite in Schizophrenia

Peter G. Falkai

Von Siebold Str. 5, 
Goettingen, NI, DE 
Clinical Trials:Currently Recruiting for 1 Trial
Elite in Schizophrenia
Von Siebold Str. 5, 
Goettingen, NI, DE 
OverviewLocationsClinical Research

Overview

Peter Falkai practices in Goettingen, Germany. Mr. Falkai is rated as an Elite expert by MediFind in the treatment of Schizophrenia. His top areas of expertise are Schizophrenia, Bipolar Disorder (BPD), Schizoaffective Disorder, and Major Depression.

His clinical research consists of co-authoring 694 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 322 articles and participated in 2 clinical trials in the study of Schizophrenia.

Gender
Male

Locations

Von Siebold Str. 5, Goettingen, NI 37075, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Enhancing Recovery in Early Schizophrenia - a Multi-center, Two-arm, Double-blind, Randomized Phase II Trial Investigating Cannabidiol Vs. Placebo As an Add-on to an Individualized Antipsychotic Treatment
Enhancing Recovery in Early Schizophrenia - a Multi-center, Two-arm, Double-blind, Randomized Phase II Trial Investigating Cannabidiol Vs. Placebo As an Add-on to an Individualized Antipsychotic Treatment
Enrollment Status: Recruiting
Publish Date: December 27, 2024
Intervention Type: Drug
Study Drug: Cannabidiol as Add-On
Study Phase: Phase 2
A Four-week, Multicentre, Double-blinded, Randomised, Active- and Placebo- Controlled, Parallel-group Trial Investigating Efficacy and Safety of Cannabidiol in Acute, Early-stage Schizophrenic Patients
A Four-week, Multicentre, Double-blinded, Randomised, Active- and Placebo- Controlled, Parallel-group Trial Investigating Efficacy and Safety of Cannabidiol in Acute, Early-stage Schizophrenic Patients
Enrollment Status: Terminated
Publish Date: December 27, 2024
Intervention Type: Drug
Study Drugs: Cannabidiol, Olanzapine
Study Phase: Phase 2
View 1 Less Clinical Trial

691 Total Publications

Schizophrenia treatment preferences of psychiatrists vs. guidelines: A European perspective.
Schizophrenia treatment preferences of psychiatrists vs. guidelines: A European perspective.
Journal: European psychiatry : the journal of the Association of European Psychiatrists
Published: August 01, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Falkai's expertise for a condition
ConditionClose
    View All 8 Advanced Conditions
    View All 22 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile